In development: Guidance, quality standards and advice

Showing 1 to 10 of 40

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	NICE guideline	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	Technology appraisal guidance	TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	TBC